Sec Form 4 Filing - Lux Encore Sponsor, LP @ Lux Health Tech Acquisition Corp. - 2020-10-29

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Lux Encore Sponsor, LP 2. Issuer Name and Ticker or Trading Symbol Lux Health Tech Acquisition Corp. [ LUXA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O LUX HEALTH TECH ACQUISITION CORP., 920 BROADWAY, 11TH FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 10/29/2020 (Street) NEW YORK, NY10010 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrants $ 11.5 10/29/2020 P 5,933,333 ( 1 ) ( 1 ) Class A Common Stock 5,933,333 $ 1.5 5,933,333 I See footnote ( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Lux Encore Sponsor, LP C/O LUX HEALTH TECH ACQUISITION CORP. 920 BROADWAY, 11TH FLOOR NEW YORK, NY10010 X Lux Encore Holdings, LLC C/O LUX HEALTH ACQUISITION CORP. 920 BROADWAY, 11TH FLOOR NEW YORK, NY10010 X Wolfe Josh C/O LUX HEALTH ACQUISITION CORP. 920 BROADWAY, 11TH FLOOR NEW YORK, NY10010 X Hebert Peter C/O LUX HEALTH ACQUISITION CORP. 920 BROADWAY, 11TH FLOOR NEW YORK, NY10010 X Signatures Lux Encore Sponsor, LP, By: Lux Encore Holdings, LLC, its general partner, By: /s/ Segolene Scarborough, Attorney-in-Fact for Peter Hebert, Managing Member and Josh Wolfe, Managing Member 11/02/2020 Signature of Reporting Person Date Lux Encore Holdings, LLC, By: /s/ Segolene Scarborough, Attorney-in-Fact for Peter Hebert, Managing Member and Josh Wolfe, Managing Member 11/02/2020 Signature of Reporting Person Date /s/ Segolene Scarborough, Attorney-in-Fact for Josh Wolfe 11/02/2020 Signature of Reporting Person Date /s/ Segolene Scarborough, Attorney-in-Fact for Peter Hebert 11/02/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The warrants will become exercisable commencing on the later of 12 months from the closing of the Issuer's initial public offering or 30 days after the completion of the Issuer's initial business combination, and will expire five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation. ( 2 )Lux Encore Sponsor, LP ("Sponsor") is the record holder of the warrants reported herein. Lux Encore Holdings, LLC ("Lux GP") is the general partner of Sponsor. Josh Wolfe and Peter Hebert are the managing members of Lux GP. As such, Lux GP and each of Messers. Wolfe and Hebert may be deemed to share beneficial ownership of the warrants held directly by Sponsor. Lux GP and Messers. Wolfe and Hebert disclaim any beneficial ownership of such shares other than to the extent of their pecuniary interest therein, if any.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.